Regenacy Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company regenerating biological function by protein acetylation for the treatment of diabetic and other peripheral neuropathies and other chronic conditions. The company’s selective inhibition technology provides superior safety profiles and potential enhanced efficacy compared to non-selective HDAC inhibitors. Regenacy selectively inhibits histone deacetylase 6 (HDAC6) to restore normal intracellular protein and organelle transport in peripheral neuropathies, and also has a portfolio of selective HDACs 1 and 2 inhibitors that have potential to treat major blood diseases such as leukemia, sickle cell disease, β-thalassemia, and cognitive dysfunction in neurological disorders.

Biotechnology

Regenacy Pharmaceuticals

Simon S. Jones

Matthew Jarpe

Timothy Kachmar

The Leadership Team at Regenacy Pharmaceuticals is responsible for setting the strategic direction of the company and overseeing the development of innovative therapies for chronic conditions. Comprising experts in clinical research, regulatory affairs, and executive management, the team ensures that the company's projects align with regulatory requirements and market needs while fostering collaboration across departments to maximize the potential of regenerative biopharmaceuticals. Their collective expertise guides critical decision-making processes to advance clinical trials and enhance the therapeutic landscape for patients with diabetes-related neuropathies and other diseases.

Leadership Team

About

Team members

Other teams at Regenacy Pharmaceuticals

Regulatory and Advisory Team